dihydroxyphenylalanine has been researched along with Dyskinesia, Drug-Induced in 19 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The long-term use of LD is limited by the development of L-DOPA-induced dyskinesias and dystonia." | 1.39 | The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. ( Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R, 2013) |
| " We retrospectively analyzed data from 17 stable HP rhesus monkeys treated long-term with chronic intermittent dosing of levodopa (LD) in an attempt to induce choreoathetoid and dystonic dyskinesias." | 1.37 | Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. ( Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T, 2011) |
| "Levodopa caused an increase in plasma growth hormone concentration in 30 subjects." | 1.26 | Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. ( Galea-Debono, A; Jenner, P; Marsden, CD; Parkes, JD; Tarsy, D; Walters, J, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Speck, AE | 1 |
| Aguiar, AS | 1 |
| Ferreira, SG | 1 |
| Silva, HB | 1 |
| Tomé, ÂR | 1 |
| Agostinho, P | 1 |
| Cunha, RA | 1 |
| Prediger, RD | 1 |
| Gutiérrez-Valdez, AL | 1 |
| García-Ruiz, R | 1 |
| Anaya-Martínez, V | 1 |
| Torres-Esquivel, C | 1 |
| Espinosa-Villanueva, J | 1 |
| Reynoso-Erazo, L | 1 |
| Tron-Alvarez, R | 1 |
| Aley-Medina, P | 1 |
| Sánchez-Betancourt, J | 1 |
| Montiel-Flores, E | 1 |
| Avila-Costa, MR | 1 |
| Alcacer, C | 1 |
| Charbonnier-Beaupel, F | 1 |
| Corvol, JC | 1 |
| Girault, JA | 1 |
| Hervé, D | 1 |
| Lieu, CA | 1 |
| Deogaonkar, M | 1 |
| Bakay, RA | 1 |
| Subramanian, T | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Juengling, FD | 1 |
| Connemann, BJ | 1 |
| Reske, SN | 1 |
| Spitzer, M | 1 |
| Kassubek, J | 1 |
| Sossi, V | 1 |
| de la Fuente-Fernández, R | 1 |
| Schulzer, M | 1 |
| Adams, J | 1 |
| Stoessl, J | 1 |
| Natesan, S | 1 |
| Svensson, KA | 1 |
| Reckless, GE | 1 |
| Nobrega, JN | 1 |
| Barlow, KB | 1 |
| Johansson, AM | 1 |
| Kapur, S | 1 |
| Wöller, W | 2 |
| Tegeler, J | 2 |
| Bennett, JP | 1 |
| Landow, ER | 1 |
| Schuh, LA | 1 |
| Narabayashi, H | 1 |
| Blanchet, PJ | 1 |
| Gomez-Mancilla, B | 1 |
| Bédard, PJ | 1 |
| Brooks, DJ | 1 |
| Perret, J | 1 |
| Feuerstein, C | 1 |
| Pellat, J | 1 |
| Serre, F | 1 |
| Gavend, M | 1 |
| Tanche, M | 1 |
| Galea-Debono, A | 1 |
| Jenner, P | 1 |
| Marsden, CD | 2 |
| Parkes, JD | 1 |
| Tarsy, D | 1 |
| Walters, J | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Nygaard, TG | 1 |
| Fahn, S | 1 |
| Nasrallah, HA | 1 |
| Dunner, FJ | 1 |
| McCalley-Whitters, M | 1 |
| Smith, RE | 1 |
| Albani, C | 1 |
| Asper, R | 1 |
| Baumgartner, G | 1 |
3 reviews available for dihydroxyphenylalanine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies.
Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Di | 1995 |
DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dihydroxyphenylalanine; Dopamine Agonists; Dy | 1995 |
PET studies and motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Fluo | 2000 |
1 trial available for dihydroxyphenylalanine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
Topics: 5-Hydroxytryptophan; Adult; Aged; Choline; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamin | 1986 |
15 other studies available for dihydroxyphenylalanine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine | 2021 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylala | 2013 |
Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dihydroxyphenylalanine; Dopaminergic Neurons; Dyskin | 2014 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carot | 2011 |
Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol.
Topics: Adult; Basal Ganglia; Benperidol; Carbon Radioisotopes; Clozapine; Dihydroxyphenylalanine; Dyskinesi | 2004 |
Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Topics: Adult; Age Factors; Age of Onset; Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agent | 2006 |
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor sid
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Binding, Competitive; Dihydroxyphenylalanine; Dop | 2006 |
[Tardive dyskinesia: clinical picture, prevalence, and pathophysiology].
Topics: Age Factors; Antipsychotic Agents; Diagnosis, Differential; Dihydroxyphenylalanine; Dyskinesia, Drug | 1983 |
[Therapeutic measures in tardive dyskinesia].
Topics: Age Factors; Amantadine; Antipsychotic Agents; Baclofen; Benzodiazepines; Bromocriptine; Deanol; Dih | 1983 |
Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.
Topics: Aged; Clozapine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; | 1993 |
[Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
Topics: Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; | 1977 |
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Levod | 1977 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Dopa-responsive dystonia: long-term treatment response and prognosis.
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Depression; Dihydroxyphenylalanine; Disab | 1991 |
[Long-term problems of levodopa therapy in Parkinson disease].
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; | 1987 |